Women harboring heterozygous germline mutations of BRCA2 have a 50-80% risk of developing breast cancer, yet the early pathogenesis of these cancers is poorly understood. We sought to reveal early steps in BRCA2-associated carcinogenesis through analysis of sorted cell populations from freshly-isolated, non-cancerous breast tissues among a cohort of BRCA2 mutation carriers and matched controls. Single-cell whole-genome sequencing demonstrates that >25% of BRCA2 carrier (BRCA2 mut/+ ) luminal progenitor (LP) cells exhibit sub-chromosomal copy number variations (CNVs), which are rarely observed in non-carriers. Correspondingly, primary BRCA2 mut/+ breast epithelia exhibit spontaneous and replication stress-induced DNA damage together with attenuated replication checkpoint and apoptotic responses, associated with an age-associated expansion of the LP compartment in human carrier tissues. These phenotypes are not associated with loss of wild-type BRCA2. Collectively, these findings provide evidence for BRCA2 haploinsufficiency and associated DNA damage in vivo that precede histologic abnormalities. These results provide unanticipated opportunities for new cancer risk assessment and prevention strategies in high-risk patients.
Introduction
Breast cancers arising in women who inherit heterozygous mutations in BRCA2 are associated with a high prevalence of genomic alterations and aggressive clinical behavior (1, 2) . Due to the high risk of these cancers in BRCA2 mutation carriers, many such women elect to undergo bilateral mastectomy for breast cancer prevention. Yet despite the unmet need for more effective breast cancer prevention approaches in this setting, the stepwise evolution from an otherwise normal BRCA2 heterozygous mutant (BRCA2 mut/+ ) cell to an invasive malignancy has not been defined.
Homozygous loss of BRCA2 is embryonic lethal (3) (4) (5) , and acute loss in cultured cells rapidly leads to DNA damage and growth arrest or cell death (6) (7) (8) . These observations suggest a multi-step pathogenesis in which homozygous BRCA2 loss is not the earliest genetic event, but rather that the wild-type BRCA2 allele may remain intact as early genetic changes accumulate. Critically however, this scenario leaves unresolved the nature and enabling mechanism for early cancer evolution. Haploinsufficiency for BRCA2 has been proposed as a possible driver of early pathogenesis, but direct evidence for such an effect in the normal human mammary gland is inconsistent. Furthermore, heterozygous genetically engineered mouse models (GEMMs) of BRCA2 are not tumor prone and therefore represent a poor model of precancerous evolution in this setting (3-5, 8, 9) . While the BRCA1 tumor suppressor shares many of these features (9, 10) , the pathogenesis of BRCA1-versus BRCA2-associated breast cancers may differ in important ways, as the former are primarily hormone receptor (HR) and HER2-negative tumors, while the latter are primarily HR-positive (11) .
We sought to unveil the earliest steps in the pathogenesis of BRCA2-associated breast tumors through detailed analysis of histologically normal glands from women harboring germline deleterious mutations who elected to undergo bilateral prophylactic mastectomy. Genomic analysis of individual cells revealed frequent polyclonal chromosomal damage, which was most prevalent among the subset of epithelial cells that are the suspected cell-of-origin of these cancers.
Corresponding defects in replication stress and DNA damage checkpoint responses in these same cells collectively define a previously unappreciated haploinsufficient phenotype for BRCA2 in the human breast. The discovery of these precancerous hallmarks paves the way for improving clinical risk prediction and cancer prevention in this population.
Results

Single-cell whole genome analysis reveals sub-chromosomal aneuploidy in BRCA2 mut/+ human primary breast epithelial cells
We carried out detailed analysis of histologically normal glands from BRCA2 carriers who elected to undergo bilateral prophylactic mastectomy, using as controls tissues from age-matched women electing cosmetic breast surgery (Fig. 1A ). We employed established markers to carry out flow cytometry-based isolation and sorting of the three major epithelial cell sub-populations: mature luminal (ML), luminal progenitor (LP) and basal epithelial cells ( Fig. 1A) . Notably, data from GEMMs and gene expression analyses of human tumors have suggested that the cell of origin of BRCA1-associated breast cancer is the LP cell (12, 13) , while BRCA2-associated tumors may arise from an LP-related cell or a more mature luminal cell (14) .
Among the earliest events in cancer evolution are thought to be polyclonal somatic genomic alterations. Accordingly, we looked for the presence of somatic CNVs at high-resolution through single-cell whole-genome sequencing (WGS) of uncultured, flow-sorted primary LP and basal epithelial cells from BRCA2 carriers and controls. Low-coverage WGS provides sufficiently high resolution to identify sub-chromosomal CNVs as small as 10MB, and our methodology for singlecell whole-genome amplification and analysis has been previously validated (15, 16) . We carried out WGS to an average depth between 0.1-0.05X, then used two independent algorithms (HMMcopy and DNAcopy) to assign and confirm copy number changes across the genome (15, 16) . Previous studies employing this methodology have demonstrated that in unselected individuals the proportion of cells with any such CNVs is very low (<5% of cells) in normal epithelial and brain tissues (16) . In contrast, among nearly 100 individual LP cells from a cohort of BRCA2 carriers analyzed by WGS we observed that 27% demonstrated one or more CNVs of >10MB ( Fig. 1, B to D). Applying this methodology to an equal number of basal breast epithelial cells from the same individuals also revealed a substantial excess of cells harboring CNVs (13%), although significantly less than the proportion of CNV-positive LP cells (p=0.04) ( Fig. 1, B to D).
By comparison, a parallel WGS analysis of sorted LP and basal cells from non-carriers revealed a single CNV in 90 cells (Fig. 1, B and C). As further validation of our sequencing and analysis pipelines we re-analyzed existing data from normal skin and brain cells sequenced on the same platform. The overall sequence quality was comparable between these cells and the breast epithelial cells, and we confirmed the low prevalence of CNV-positive cells in 142 skin and brain cells sequenced (fig. S1). Thus, breast epithelia and particularly LP cells from non-cancerous breast tissue of BRCA2 carriers harbor frequent sub-chromosomal aneuploid events ( Fig. 1D, fig.   S2A ).
One notable CNV we observed was duplication of the entire chromosome 1q arm, which is a common genomic abnormality in breast cancer ( Fig. 2A) (17) . The majority of the identified CNVs were sub-chromosomal haploid losses, consistent with the widespread pattern of losses observed 6 in BRCA2-associated breast cancer ( Fig. 2A and fig. S2B ) (1). In some cases, identical losses were shared between multiple cells of the same patient, a finding which could conceivably correspond to early clonal evolution ( Fig. 2B ). Importantly, none of the losses in any cell involved the BRCA2 locus on chromosome 13 ( Fig. 1B and fig. S2 , B to E). Prior analyses of germline BRCA2associated breast cancers have demonstrated that most genetic loss-of-heterozygosity (LOH) events for BRCA2 itself are >10MB and therefore would have been detected by our analysis (18) .
This observation suggests that the wild type BRCA2 allele is intact in our cases, implying that accumulation of sub-chromosomal aneuploidy may be a haploinsufficient phenotype. To confirm the integrity of the wild-type allele we performed targeted PCR amplification of the locus surrounding the patient-specific BRCA2 mutation from individual cells. Although efficiency for detection of either allele was relatively low, in no case did we identify a cell with a detectable mutant allele and no detectable wild-type allele (Fig. 2C ). Taken together, these findings imply that sub-chromosomal aneuploidy is an early, haploinsufficient phenotype in BRCA2 mut/+ breast epithelia.
BRCA2 mut/+ primary cells exhibit DNA damage and a deregulated replication stress response
The presence of viable aneuploid cells in BRCA2 mut/+ tissues suggested ongoing DNA damage and a deregulated stress or damage response. Thus, we next used an independent method to directly assess DNA damage in single cells, the comet assay. This assay employs cells embedded in agarose that are lysed then subjected to electrophoresis, causing broken DNA structures to migrate toward the anode, thus forming a comet tail (19) . We briefly cultured freshly-collected cells from BRCA2 carriers or controls under ultra-low attachment conditions (48-72h) to select for epithelial progenitor cells prior to plating (20) . Consistently, cells from BRCA2 carriers demonstrated increased DNA breaks at baseline compared to controls (Fig. 3A) . Additionally, inducing replication stress by treatment with hydroxyurea (HU) led to further increases in DNA damage in BRCA2 mut/+ cells, potentially reflecting the established role of BRCA2 in protection of stalled replication forks ( Fig. 3A) (21) .
We then examined the response to this genomic stress by analyzing phosphorylation of CHK1, a central coordinator of the response to replication stress and DNA damage (22, 23) . Cytospins of primary epithelial progenitor cultures prepared as above were stained for phosphorylated CHK1 at baseline or following 4 hours of exposure to HU. As anticipated, control primary epithelia exhibited increased CHK1 phosphorylation within 4 hours of HU treatment ( Fig. 3B ). In contrast, however, cells from BRCA2 carriers exhibited a failure to active CHK1 in response to HU, despite normal levels of total CHK1 protein ( Fig. 3B and fig. S3A ). DNA sequencing of these cells revealed the presence of both wild-type and mutant BRCA2 alleles ( fig. S3B ). These findings provide further support for a haploinsufficient phenotype of BRCA2 in the response to genomic stress.
Because we observed a deregulated genomic stress response in vitro, we wanted to know whether this also occurs in vivo. Thus, we carried out RNA-seq analysis of freshly-sorted LP and basal epithelial cell populations from BRCA2 carrier tissues or controls ( Fig. 1A ). Analysis of these data revealed enrichment in BRCA2 mut/+ LP cells of an established signature reflecting a failure of the ATR/CHK1-mediated replication stress checkpoint in non-transformed mammary epithelial cells ( Fig. 3C and fig. S3C ) (24) . This replication stress response deficiency (RSRD) signature is known to predict future cancer risk (24) , and it contains some of the top most differentially expressed genes between BRCA2 mut/+ and control LP cells ( Fig. 3C ). Among these are genes of potential relevance to HR-positive breast cancer (which comprise 80% of BRCA2-associated breast cancers), including the estrogen receptor target gene HOXC4 and the GATA transcription factor binding partner gene ZFPM1 (Fig. 3C) (25, 26) . Furthermore, evaluation of differentially expressed programs through Gene Set Enrichment Analysis revealed the highly significant deregulation of a radiation response signature in BRCA2 mut/+ LP cells ( fig. S3D ) (27) . Notably, the differential expression of this signature between BRCA2 mut/+ and control cells was far more significant within the LP compared to the basal population, in keeping with the more frequent occurrence of CNVs among LP cells ( fig. S3D ). Again consistent with haploinsufficiency for BRCA2, the RNA-seq data showed no evidence for exclusive expression of the mutant allele in BRCA2 mut/+ LP cells ( fig. S3E ). Thus, BRCA2 mut/+ LP cells exhibit evidence of aberrant replication stress and DNA damage responses in vivo.
BRCA2 mut/+ LP cells show increased TP53 activity and decreased NF-kB/SASP pathway expression
We then turned to examine the downstream consequences of the DNA damage detected in LP cells of BRCA2 carriers. A hallmark genetic event that cooperates with BRCA2 deficiency in cancer pathogenesis is loss of TP53, suggesting that activation of TP53 may be an early barrier to malignant progression in this setting (28) . We therefore hypothesized that the failed CHK1dependent replication stress response we observed might ultimately lead to DNA double-strand breaks and thereby trigger TP53 activation through a CHK1-independent pathway (29). Indeed, recent studies suggest CHK1 is not required for TP53 activation in primary breast epithelial cells following DNA damage (30) . RNA-seq analysis did suggest activation of TP53 in BRCA2 mut/+ LP 9 cells, evidenced by the increased expression of multiple direct TP53 target genes ( Fig. 4A) (31, 32) . This TP53 activation in vivo was associated with a strong transcriptional profile indicating suppression of NF-kB signaling, including numerous cytokine and inflammatory factors associated with the senescence-associated secretory phenotype (SASP) ( Fig. 4, B to D). TP53 is known to suppress the NF-kB/SASP response (33, 34) , and this effect is emerging as a relevant component of TP53-dependent tumor suppression given that accumulation of SASP-expressing cells is an established driver of tumorigenesis (35) . We independently validated the corresponding alterations in NF-kB protein expression, demonstrating that the NFKB1 (p50) and NFKB2 (p52) subunits were expressed at lower levels in BRCA2 carrier tissues compared to controls ( Fig. 4C ). 
Age-associated deregulation of breast epithelial cell proportions in BRCA2 carriers suggests expansion of a damaged LP cell population over time
Deregulated DNA damage and senescence/SASP responses in BRCA2 LP cells might be expected to alter the proportion of these cells over time (36) . We thus sought to address whether there were differences in the proportions of progenitor or other epithelial sub-populations in BRCA2 mut/+ tissues compared to controls. We collected a larger cohort of tissues from BRCA2 carriers (N=26) and controls (N=28), then performed flow cytometry analysis on these specimens and plotted the proportions of each epithelial sub-population as a function of age for each cohort (Fig. 5A ). In non-carrier controls no significant age-associated changes in the prevalence of these subpopulations were noted. In contrast, BRCA2 carriers showed an age-associated expansion in the proportion of LP cells and a decline in the basal cell fraction ( Fig. 5B and fig. S5, A and B ). These differences were not accounted for by demographic factors such as parity or menopausal status, as such factors were not associated with significant differences in epithelial cell proportions (fig. S5, C and D). Thus, DNA-damage and suppression of a senescence-associated program in BRCA2 mut/+ LP cells is accompanied by an age-associated expansion of this progenitor cell compartment (36) .
Finally, we hypothesized that altered epithelial cell proportions in BRCA2 carrier tissues may be associated with differences in cell proliferation and/or survival in vivo. The relationship between NF-kB/SASP program, proliferation and susceptibility to apoptosis is a cell-type and contextdependent one (36) . We did not observe strong differences in proliferation assessed by Ki67 staining between these BRCA2 carrier breast tissues and controls (not shown), prompting us to ask whether differences in cell survival might contribute to the age-associated expansion of the LP population in this context. We therefore carried out TUNEL staining, an established marker of apoptosis, in BRCA2 carrier tissues and controls. The proportion of TUNEL-positive cells is welldocumented in normal human breast epithelial tissues, and we observed a similar prevalence of these cells in the control tissues we tested ( Fig. 5C) (37) . In contrast, however, BRCA2 mutation carrier tissues consistently showed a paucity of TUNEL-positive luminal epithelial cells across all patients tested, in keeping with established links between checkpoint and NF-kB suppression and a defective apoptotic response ( Fig. 5C) (38, 39) . Collectively, our findings suggest that BRCA2 haploinsufficiency is associated with an age-associated accumulation of DNA-damaged luminal epithelial progenitor cells bearing altered checkpoint and survival responses ( fig. S6 ).
Discussion
This study advances our understanding of early changes in BRCA2 mut/+ breast tissues, defining unanticipated phenotypes in this setting with implications for both cancer risk assessment and prevention. The majority of the tissues we studied were deemed to be histologically normal by highly experienced breast pathologists, suggesting that the alterations we report precede clinicallydefined cellular abnormalities (tables S1, S2). We present evidence that a failed replication stress response and DNA damage in BRCA2 mut/+ tissues results from haploinsufficiency for BRCA2 rather than homozygous loss of function. While the presence of haploinsufficiency for either BRCA1 or BRCA2 in vivo has been controversial, our findings are in accord with data suggesting that LOH for the wild-type BRCA2 is not universal in BRCA2-associated cancers (40) . Our observations are also in keeping with a recent report that the BRCA2 protein is selectively susceptible to degradation by environmental aldehydes (41) , an effect which could contribute to a haploinsufficient phenotype in cells with only one functional BRCA2 allele. Nonetheless, our study of early pathogenesis does not prove that haploinsufficiency is sufficient for progression to invasive malignancy, but rather we define a haploinsufficient phenotype for BRCA2 that is a potential initiating event for these cancers.
A prominent feature of the phenotype we have uncovered is frequent sub-chromosomal aneuploidy, most prevalent within the LP cell population. LP cells are a potential target cell for BRCA2-associated carcinogenesis in the breast, and indeed we observe instances of apparently clonally related genomic alterations among these cells. Such alterations could conceivably represent the earliest somatic genetic abnormalities that underlie these malignancies. Notably, all the CNVs we identified were sub-chromosomal and therefore are to be distinguished from wholechromosome gains and losses that are typically later events and are associated with TP53 inactivation (42) . Although these early genomic changes are likely to include many passenger events, they nevertheless may provide a quantifiable hallmark of the pre-neoplastic BRCA2 carrier state. Tracking the prevalence of DNA-damaged cells in the clinical setting could possibly improve risk prediction for such women, who are faced with the difficult choice of whether to undergo mastectomy long before cancer develops. Finally, the BRCA2 haploinsufficient phenotype we report may portend particular vulnerabilities of certain BRCA2 mut/+ cancer precursor cells.
Accordingly, this work provides a foundation for future studies seeking to identify novel pharmacologic approaches to cancer prevention in this setting.
Materials and Methods
Human breast tissues
Fresh human breast tissues were obtained from Massachusetts General Hospital with approval by the local Institution Review Board and signed informed patient consent (Protocols 93-085 and 2008-P-1789). Samples were either normal breast tissues from reduction mammoplasties (confirmed by pathology) or non-cancerous breast tissues from prophylactic mastectomies of known BRCA1 or BRCA2 mutation carriers. All BRCA1/2 carrier status was determined through clinical germline genetic testing performed by commercial providers prior to tissue collection.
Mammary cell preparations
Tissue samples were minced and digested with collagenase/hyaluronidase (Stemcell technologies) in complete Epicult-B Medium supplemented with 0.48 g/mL hydrocortisone (Stemcell technologies) overnight at 37 C. The resulting suspensions were either cryopreserved or further sequentially digested with 0.25% trypsin, 5 mg/mL dispase and 1 mg/mL DNase I. Single cell suspensions were collected by filtration through a 40 m cell strainer.
Cell staining and sorting
Cells were blocked with rat immunoglobulin (Jackson Immunolabs) and antibody to Fc receptor binding inhibitor (eBioscience) before incubation with the following primary antibodies: PEconjugated anti-human CD31 (BD Pharmingen), PE-conjugated anti-human CD45 (BD Pharmingen), PE-conjugated anti-human CD235a (BD Pharmingen), BV650-conjugated antihuman EPCAM CD326 (Biolegend), biotin-conjugated anti-human ITGA6 (eBioscience). Where required, cells were incubated with APC-Cy7-conjugated streptavidin (BD Pharmingen). Cells were either stained with DAPI for viability or fixed with 1% PFA and stained with zombie aqua fixable viability kit (Biolegend). Viable cells were sorted on a FACSAria flow cytometer (Becton Dickinson). Data was analyzed using FlowJo software (Tree Star). 
Single-Cell PCR for allele-specific LOH analysis
Immunostaining
Immunofluorescence for paraffin sections and TUNEL staining were performed by Dana-Farber/Harvard Cancer Center Specialized Histopathology Core. For Immunofluorescence in cells, fixation was performed with methanol for 10 min followed by permeabilization in 0.1% TritonX100 for 2 min. Blocking was performed with 10% horse serum for 30 min and cells were further incubated with primary p-CHK1 antibody (Novus Biologicals) for 2 hr, washed with wash buffer (PBS +10% horse serum + 0.1% TritonX100), incubated with appropriate secondary antibody for 1hr and stained with DAPI. All immunofluorescence images were captured by a confocal microscope (Leica TCS SP8) and were analyzed by ImageJ.
Western Blotting
Snap-frozen tissues were homogenized using Precellys 24 homogenizer (Bertin Technologies).
For total protein extraction, cells were lysed in RIPA buffer (10 mM Tris-HCl pH 7.5, 150 mM NaCl, 1 mM EDTA, 1% sodium deoxycholate, 0.1% (w/v) SDS, 1% (v/v) NP40, proteinase inhibitor cocktail, phosphatase inhibitor cocktail) for 30 min on ice. Western blotting was performed using NFKB p50 (Santa Cruz Biotechnologies) and NFKB p52 (Millipore) antibodies by standard protocol.
Single-Cell Copy Number Analysis
Fresh tissues were dissociated as described above and single cells were isolated by microaspiration. Genomic DNA was amplified and sequenced as described in Knouse et al. 2014 .
Fastqs were aligned using bwa-mem, with resulting bams sorted and duplicates marked using Picard. Coverage was then computed over 500kb bins across the entire genome. The count for each bin was then divided by the sum across all bins for the relative sample (to correct for library size), and then by the median for that genomic bin across all samples from the same batch. The coverage profiles were then transformed into .wig files and fed into the R package HMMCopy for segmentation and CNV-calling. HMMCopy was run with e = 0.9999999 and nu = 5, with all other parameters set to default. A noise statistic termed "VS" was computed in the same manner as Knouse et al. 2014 , with cells with values greater than or equal to 0.5 being excluded from the analysis. CNVs that mapped to the Y chromosome, were less than 10Mb in size, or had an absolute log2 ratio less than 0.4 were excluded from the analysis.
RNA-Seq Analysis
Total RNA from sorted cell populations was extracted using RNeasy FFPE kit, according to 
Other Statistical Methods
p Values were determined using the Student's unpaired t test unless indicated otherwise.
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